Why the study?
What are the risk factors and optimal management strategies for antepartum venous thromboembolism?
What are the risk factors and optimal management strategies for antepartum venous thromboembolism?
The use of lactation-suppressing estrogens in patients with antepartum venous thromboembolism is associated with puerperal pulmonary embolism and should be avoided.
Answers are grounded in this paper and cite their sources.
Lactation suppression with stilboestrol or hexoestrol was associated with puerperal PE; hypothesis-generating for VTE risk in antepartum patients.
Summary Thirty‐four patients with antenatal venous thromboembolism seen in Dundee Royal Infirmary between 1960 and 1969 are reviewed in an attempt to define the patient at risk. No pregnant woman is immune but older parous patients with a history of venous trouble and subjected to rest in bed are likely to develop the condition. The diagnosis of deep venous thrombosis and the medical management of patients with antenatal deep venous thrombosis are discussed. There may be a place for the use of low molecular weight Dextran during labour and in the early puerperium. Although postpartum recurrence of deep venous thrombosis did not occur significantly more frequently in patients who had received stilboestrol to suppress lactation, all the cases of puerperal pulmonary embolism occurred in patients who had received either stilboestrol or hexoestrol. It appears unwise to administer substances which are known to raise blood clotting factors to patients who are already notably susceptible to venous thrombosis. Antepartum and postpartum anticoagulation regimens are suggested.
No takes yet. Share an insight, caveat, or question.
Duncan et al. (1971) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: